Associated Papers
Molecular Mosaics: Unveiling Heterogeneity in Synchronous Colorectal Cancers.
Lee HG et al.
Cancer Research and Treatment, 2026
The Occurrence of Gene Fusions in Thyroid Lesions and the Relation With Chronic Lymphocytic Thyroiditis.
Jentus MM et al.
Pathology International, 2026
A prospective, multicenter, comprehensive genomic profile signature study in patients with EGFR-mutant advanced non-small cell lung cancer at the first-line treatment failure of osimertinib.
Shi Y et al.
Signal Transduction and Targeted Therapy, 2025
High depth targeted next-generation sequencing in vascular malformations.
Pakhathirathien P et al.
Human Molecular Genetics, 2025
Comprehensive analysis of oncogenic determinants across tumor types via multi-omics integration.
Ubaid S et al.
Cancer Genetics, 2025
Genetic Alteration Profiling in North Macedonian Lung Cancer Patients.
Eftimov A et al.
Genes, 2025
Profiling of HER2, KRAS, and PIK3CA mutations in uterine cervical neuroendocrine carcinoma and implications for oncogenic driver targeting therapy.
Chao WR et al.
Cancer Genetics, 2025
Identification of Somatic Genetic Variants in Superficial Vascular Malformations by Liquid Biopsy in a Cohort of 88 Patients from a French Hospital.
El Sissy FN et al.
Molecular Diagnosis & Therapy, 2025
Frequency of targetable genetic alterations in resectable lung adenocarcinoma: Results from the LORD project.
Bossé Y et al.
Lung Cancer (amsterdam, Netherlands), 2025
Comprehensive Genomic Profiling of Indian Patients With Lung Cancer.
Sharma S et al.
Jco Global Oncology, 2025
Histone H3E50K remodels chromatin to confer oncogenic activity and support an EMT phenotype.
Sad K et al.
Nar Cancer, 2025
A stratified two-stage tumor molecular profiling algorithm to identify clinically actionable molecular alterations in pancreatic cancer.
Hussung S et al.
Esmo Gastrointestinal Oncology, 2025
Molecular identification of KRAS, BRAF, and PIK3CA mutations in colorectal cancer patients from the Kurdistan region of Iraq.
Hamasharif HG
Molecular Biology Research Communications, 2025
PIK3CA Mutations and Co-Mutations in Operated Non-Small Cell Lung Carcinoma.
Cokpinar S et al.
Journal of Clinical Medicine, 2024
Molecular characteristics of advanced colorectal cancer and multi-hit PIK3CA mutations.
Yasin F et al.
The Oncologist, 2024
Survey for Activating Oncogenic Mutation Variants in Metazoan Germline Genes.
Krueger KE
Journal of Molecular Evolution, 2024
Detection of genetic mutations in 855 cases of papillary thyroid carcinoma by next generation sequencing and its clinicopathological features.
Shi D et al.
Diagnostic Pathology, 2024
Molecular characterization of Chinese patients with small bowel adenocarcinoma.
Jin B et al.
Clinical & Translational Oncology : Official Publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico, 2024
Characterizing multi-PIK3CA mutations across cancer types: Toward precision oncology.
Nakamura K et al.
Cancer Medicine, 2024
Detection of Single Nucleotide Polymorphisms of Circulating Tumor DNA by Strand Displacement Amplification Coupled with Liquid Chromatography.
Ma Z et al.
Analytical Chemistry, 2024
Negative Hyperselection of Resistance Mutations for Panitumumab Maintenance in RAS Wild-Type Metastatic Colorectal Cancer (PanaMa Phase II Trial, AIO KRK 0212).
Stahler A et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research, 2024
Genetic alterations in thyroid cancer mediating both resistance to BRAF inhibition and anaplastic transformation.
Lee M et al.
Oncotarget, 2024
Association of mutation profiles with metastasis in patients with non-small cell lung cancer.
Li Y et al.
Frontiers in Oncology, 2024
Whole-exome sequencing of rectal neuroendocrine tumors.
Li Y et al.
Endocrine-related Cancer, 2023
Clinical, Pathological and Molecular Insights on KRAS, NRAS, BRAF, PIK3CA and TP53 Mutations in Metastatic Colorectal Cancer Patients from Northeastern Romania.
Afrăsânie VA et al.
International Journal of Molecular Sciences, 2023
Targeting RAF Isoforms and Tumor Microenvironments in RAS or BRAF Mutant Colorectal Cancers with SJ-C1044 for Anti-Tumor Activity.
Hong S et al.
Current Issues in Molecular Biology, 2023
Evaluation of the Analytical Performance of Oncomine Lung cfDNA Assay for Detection of Plasma EGFR Mutations.
Cho YG et al.
Genes, 2023
Histological and Genetic Diversity in Ovarian Mucinous Carcinomas: A Pilot Study.
Razia S et al.
Current Oncology (toronto, Ont.), 2023
Genetic landscape and personalized tracking of tumor mutations in Vietnamese women with breast cancer.
Nguyen Hoang VA et al.
Molecular Oncology, 2023
Preoperative Mutational Analysis of Circulating Tumor Cells (CTCs) and Plasma-cfDNA Provides Complementary Information for Early Prediction of Relapse: A Pilot Study in Early-Stage Non-Small Cell Lung Cancer.
Markou AN et al.
Cancers, 2023
Paired Comparison of Routine Molecular Screening of Patient Samples with Advanced Non-Small Cell Lung Cancer in Circulating Cell-Free DNA Using Three Targeted Assays.
Barthelemy D et al.
Cancers, 2023
Electrochemical biosensors for analysis of DNA point mutations in cancer research.
Ondraskova K et al.
Analytical and Bioanalytical Chemistry, 2023
Development of a multiplex allele-specific qPCR approach for testing PIK3CA mutations in patients with colorectal cancer.
Oscorbin IP et al.
Heliyon, 2022
Clinicopathologic Characteristics and Outcomes for Patients With KRAS G12D-Mutant NSCLC.
Cooper AJ et al.
Jto Clinical and Research Reports, 2022
The Prevalence of BRAF, PIK3CA, and RAS Mutations in Indian Patients with Colorectal Cancer.
Shetty O et al.
South Asian Journal of Cancer, 2022
Intertumor and intratumor heterogeneity of PIK3CA mutations in extramammary Paget's disease.
Kusaba Y et al.
The Journal of Dermatology, 2022
Utility of Select Gene Mutation Detection in Tumors by the Idylla Rapid Multiplex PCR Platform in Comparison to Next-Generation Sequencing.
Nkosi D et al.
Genes, 2022
Somatic activating BRAF variants cause isolated lymphatic malformations.
Zenner K et al.
Hgg Advances, 2022
DIPG Harbors Alterations Targetable by MEK Inhibitors, with Acquired Resistance Mechanisms Overcome by Combinatorial Inhibition.
Izquierdo E et al.
Cancer Discovery, 2022
Therapeutic implications of activating noncanonical PIK3CA mutations in head and neck squamous cell carcinoma.
Jin N et al.
The Journal of Clinical Investigation, 2021
EGFR Pathway-Based Gene Signatures of Druggable Gene Mutations in Melanoma, Breast, Lung, and Thyroid Cancers.
Raevskiy M et al.
Biochemistry. Biokhimiia, 2021
NGS-based liquid biopsy profiling identifies mechanisms of resistance to ALK inhibitors: a step toward personalized NSCLC treatment.
Sánchez-Herrero E et al.
Molecular Oncology, 2021
Diverse mechanisms activate the PI 3-kinase/mTOR pathway in melanomas: implications for the use of PI 3-kinase inhibitors to overcome resistance to inhibitors of BRAF and MEK.
Tran KB et al.
Bmc Cancer, 2021
Genomic and signalling pathway characterization of the NZM panel of melanoma cell lines: A valuable model for studying the impact of genetic diversity in melanoma.
Tran KB et al.
Pigment Cell & Melanoma Research, 2021
Clinical Application of Targeted Deep Sequencing in Metastatic Colorectal Cancer Patients: Actionable Genomic Alteration in K-MASTER Project.
Lee Y et al.
Cancer Research and Treatment, 2021
Cell-free DNA as a diagnostic analyte for molecular diagnosis of vascular malformations.
Zenner K et al.
Genetics in Medicine : Official Journal of the American College of Medical Genetics, 2021